BMY vs. MDT

In the year-to-date period, BMY achieves a -13.45% return, which is significantly lower than MDT's 6.19% return. Over the past 10 years, BMY has underperformed MDT with an annualized return of 0.23%, while MDT has yielded a comparatively higher 3.53% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Medtronic plc (MDT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMY Sharpe Ratio is 0.08, which is lower than the MDT Sharpe Ratio of 0.33. The chart below compares the historical Sharpe Ratios of BMY and MDT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

BMY's dividend yield for the trailing twelve months is around 5.09%, more than MDT's 3.33% yield.

The maximum BMY drawdown since its inception was -70.62%, which is greater than MDT's maximum drawdown of -57.63%. Use the drawdown chart below to compare losses from any high point for BMY and MDT. For additional features, visit the drawdowns tool.

Bristol-Myers Squibb Company (BMY) and Medtronic plc (MDT) have volatilities of 9.92% and 9.60%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Medtronic plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.